It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Treatment
Currently, there is no proven, safe treatment for monkeypox virus infection. For purposes of controlling a monkeypox outbreak in the United States, smallpox vaccine, antivirals, and vaccinia immune globulin (VIG) can be used.
(Precision Vaccinations)
Denmark-based Bavarian Nordic A/S announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) exercised the first options under an existing contract to supply a freeze-dried version of the JYNNEOS® smallpox vaccine.
The first doses of this vaccine version will be manufactured and invoiced in 2023 and 2024.
If exercised, additional options on the BARDA contract support the conversion of up to a total of approximately 13 million freeze-dried doses of JYNNEOS smallpox vaccine that are expected to be manufactured in 2024 and 2025.
To protect people from monkeypox, the Jynneos vaccine was approved by the U.S. FDA in 2019.
*and*
Additional monkeypox outbreak news is posted at Vax-Before-Travel
JYNNEOS (MVA-BN) Smallpox (Monkeypox) Vaccine - JYNNEOS® is the only FDA-approved non-replicating smallpox and monkeypox vaccine for non-military use.
Texas and Maryland each reported a monkeypox case in 2021 in people with recent travel to Nigeria.
May 18, 2022 - the Massachusetts Department of Public Health confirmed a man was hospitalized with the monkeypox after traveling to Canada.
In the spring of 2003, monkeypox cases were confirmed in the USA. Most patients were reported to have had close contact with pet prairie dogs infected by African rodents imported into the country from Ghana.
How do you catch it?
Primarily, from an animal bite, scratch or contact with the animal's bodily fluid. Then the virus can spread to other people through coughing and sneezing or contact with pus from the lesions.
The lesions from monkeypox are similar to those from a smallpox infection.
"But it doesn't spread very well between people," Hooper says. "Its infection rate is much lower than that of smallpox." In many cases, people don't spread the virus to anyone else.
Up until this current outbreak, a person sick with monkeypox spreads the virus to between zero and one person, on average. So all previous outbreaks (up until now) burned themselves out quickly.
"You have primary cases, in which people get monkeypox from an animal, and they may transmit the disease a few generations — but then that's it," she says. "The outbreaks tend to be self-limiting."
"There is no evidence, to date, that person-to-person transmission alone can sustain monkeypox infections in the human population," the World Health Organization's website says
There are two clades of monkeypox virus: the West African clade and Congo Basin (Central African) clade. Although the West African clade of monkeypox virus infection sometimes leads to severe illness in some individuals, disease is usually self-limiting. The case fatality ratio for the West African clade has been documented to be around 1%, whereas for the Congo Basin clade, it may be as high as 10%. Children are also at higher risk, and monkeypox during pregnancy may lead to complications, congenital monkeypox or stillbirth.
Milder cases of monkeypox may go undetected and represent a risk of person-to-person transmission. There is likely to be little immunity to the infection in those travelling or otherwise exposed, as endemic disease is normally geographically limited to parts of West and Central Africa. Historically, vaccination against smallpox was shown to be protective against monkeypox. While one vaccine (MVA-BN) and one specific treatment (tecovirimat) were approved for monkeypox, in 2019 and 2022 respectively, these countermeasures are not yet widely available, and populations worldwide under the age of 40 or 50 years no longer benefit from the protection afforded by prior smallpox vaccination programmes.
Historical sources suggest that in the 1800s, when smallpox still posed a serious threat, the Micmac native Americans of Nova Scotia treated the disease using a botanical infusion derived from the insectivorous plant Sarracenia purpurea, a species of pitcher plant.
There is much scepticism on herbal medicine but what our results illustrate conclusively is that this herb is able to kill the virus and we can actually demonstrate how it kills the virus,’ says Langland. ’It takes this herb out of the realm of folklore, and into the area of true scientific evidence
The team made extracts of S. purpurea and found that it was highly effective at inhibiting the replication of the virus in rabbit kidney cells. They then looked at the replication cycle of the virus and found that the herb inhibits mRNA synthesis, halting production of proteins vital for replication. ’Other drugs are being developed against smallpox, but S. purpurea is the only known therapy that will target the virus at this point in the replication cycle,’ says Langland.
originally posted by: optimisticcontrarian
a reply to: putnam6
Coeur D'alene here! Great to see another spud on!
I dont put much stock in ANY news agency any more though, def not Idahos news agencies after weve seen how hard left they turned over the last 7 years, they are full bore compliant with the agenda